CD8A and neoplasm: Non-neuroendocrine tumors have demonstrated significantly higher CD45+ leucocytes with increased CD8+ effector tumor-infiltrating lymphocytes (TILs) and higher MHC I expression, which likely contribute to variations in immunotherapy response[44-47].